Study on Platinum-Based Chemotherapy With or Without INCMGA00012 for Advanced Non-Small Cell Lung Cancer

Inclusion Criteria

• Diagnosed with advanced non-small cell lung cancer (NSCLC), either squamous or nonsquamous type, at Stage IV.
• Have not received any previous treatment for advanced or metastatic NSCLC.
• Able to provide a sample of tumor tissue for testing.
• Have at least one tumor that can be measured by scans.
• Be in good overall health, with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of at least 3 months.
• Agree to use effective birth control to prevent pregnancy during the study.
• Have good organ function as shown by specific lab tests.
• Have been fully vaccinated against COVID-19 or be willing to get vaccinated during the study.

Exclusion Criteria

• Have had serious heart problems within the last 6 months.
• Have had major surgery within 3 weeks before starting the study treatment.
• Have had high-dose radiation therapy to the chest within the last 6 months.
• Have a history of nerve damage that could be worsened by certain chemotherapy drugs.
• Have untreated cancer that has spread to the brain or spinal cord.
• Have lung diseases that required treatment with steroids.
• Have an active infection or tuberculosis that needs treatment.
• Have certain types of superficial cancers or in situ cancers.
• Have allergies or contraindications to the chemotherapy drugs used in the study.
• Have an active autoimmune disease that needed treatment in the last 2 years.
• Are taking antibiotics or steroids within 7 days before starting the study treatment.
• Have received a live vaccine within 30 days before starting the study treatment.
• Have active hepatitis B or C infections.